Therapixel SA – Trademark Portfolio

Entity Type: 99

Therapixel SA holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 2 filings in this category. The portfolio also extends into Class 9 (Computers & Electronics) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include THERAPIXEL and MAMMOSCREEN. The owner is based in Paris.

Pepinière Paris Santé Cochin

27 Rue du Faubourg Saint-Jacques

Paris 75014 , FR

3 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Therapixel SA's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

42
Computer & Scientific (2 filings)

Scientific and technological services; industrial analysis and research services

9
Computers & Electronics (1 filing)

Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments

Frequently Asked Questions

How many trademarks does Therapixel SA have?

Therapixel SA has 3 U.S. trademarks filed with the USPTO. Of these, 2 registered, 1 abandoned.

What trademark classes does Therapixel SA file in?

Therapixel SA files trademarks across 2 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 9 (Computers & Electronics). Class 42 covers scientific and technological services; industrial analysis and research services.

What are Therapixel SA's most well-known trademarks?

Therapixel SA's registered trademark portfolio includes well-known marks such as THERAPIXEL and MAMMOSCREEN. These are among 2 currently registered trademarks in the portfolio.

What is Therapixel SA's trademark registration success rate?

Therapixel SA has a 67% trademark registration rate, with 2 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.